55
Participants
Start Date
October 27, 2022
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2027
hypofractionated radiation therapy
"* Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~* Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~* Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity."
Jiangsu Cancer Hospital, Nanjing
Jiangsu Cancer Institute & Hospital
OTHER